title: Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
abstract: Health-related quality of life (HRQOL) is an important goal of therapy for chronic myeloid leukemia (CML) patients treated with current molecular-targeted therapies. The main objective of this study was to investigate factors associated with long-term HRQOL outcomes of CML patients receiving imatinib. Analysis was performed on 422 CML patients recruited in an observational multicenter study. HRQOL was assessed with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). Key socio-demographic and clinical data were investigated for their association with HRQOL outcomes. Chronic fatigue and social support were also investigated. Univariate and multivariate linear regression analyses were used to identify independent factors associated with HRQOL outcomes. Fatigue was the only variable showing an independent and consistent association across all physical and mental HRQOL outcomes (P<0.01). Differences between patients reporting low versus high fatigue levels were more than eight and seven times the magnitude of a clinically meaningful difference, respectively, for the role physical (Δ=70 points) and emotional scale (Δ=63 points) of the SF-36. Fatigue did not occur as an isolated symptom and was most highly correlated with musculoskeletal pain (r=0.511; P≤0.001) and muscular cramps (r=0.448; P≤0.001). Chronic fatigue is the major factor limiting HRQOL of CML patients receiving imatinib.
authors: Italian Group for Adult Hematologic Diseases, Data Center and Health Outcomes Research Unit, Rome, Italy. f.efficace@gimema.it
authors: F
authors: F
authors: Efficace
authors: M
authors: M
authors: Baccarani
authors: M
authors: M
authors: Breccia
authors: F
authors: F
authors: Cottone
authors: G
authors: G
authors: Alimena
authors: G L
authors: GL
authors: Deliliers
authors: C
authors: C
authors: Baratè
authors: G
authors: G
authors: Specchia
authors: R
authors: R
authors: Di Lorenzo
authors: L
authors: L
authors: Luciano
authors: D
authors: D
authors: Turri
authors: B
authors: B
authors: Martino
authors: F
authors: F
authors: Stagno
authors: M
authors: M
authors: Dabusti
authors: M
authors: M
authors: Bergamaschi
authors: P
authors: P
authors: Leoni
authors: M P
authors: MP
authors: Simula
authors: L
authors: L
authors: Levato
authors: C
authors: C
authors: Fava
authors: D
authors: D
authors: Veneri
authors: S
authors: S
authors: Sica
authors: A
authors: A
authors: Rambaldi
authors: G
authors: G
authors: Rosti
authors: M
authors: M
authors: Vignetti
authors: F
authors: F
authors: Mandelli
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D015673:Fatigue Syndrome, Chronic / Q000150:complications* / Q000523:psychology; D005260:Female; D006306:Health Surveys; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009120:Muscle Cramp / Q000150:complications / Q000523:psychology; D059352:Musculoskeletal Pain / Q000150:complications / Q000523:psychology; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011788:Quality of Life; D012919:Social Behavior; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate